Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. is a publicly traded biotechnology firm with a focus on fibrotic and inflammatory disease therapeutics. The company was founded in 2010 as a spinout from Tel Aviv University, operating initially as a private entity before listing on the Nasdaq in 2021. Wealth origin for the founding team is not publicly disclosed as a family office structure; the firm is a biotech asset manager accountable to public shareholders. The investment strategy centers on the development of CM-101, a monoclonal antibody targeting CCL24, a chemokine implicated in fibrosis and inflammation. The company's pipeline includes indications such as primary sclerosing cholangitis, systemic sclerosis, and non-alcoholic steatohepatitis. Funding has been raised through public equity offerings and private placements, with support from institutional investors. Geographic operations span Israel and the United States, with clinical trials conducted in multiple countries. Team size is limited to executive and scientific personnel, with no disclosed professionals count. The firm maintains headquarters in Tel Aviv, with additional operations in New York. No adjacent philanthropic vehicles or family-office structures have been identified. In November 2024, Chemomab presented Phase 2 data for CM-101 in primary sclerosing cholangitis at a major hepatology conference (per clinical trial registries, 2024). The firm's structural differentiator is its publicly traded biotech model, which differs from traditional single-family offices. It must balance drug-development risk with shareholder returns, relying on equity markets for capital rather than private family wealth. This governance structure requires SEC compliance and quarterly reporting, adding transparency but limiting strategic flexibility.